EP 1578792 A2 20050928 - NOVEL CENTROSOME-ASSOCIATED PROTEIN AND APPLICATIONS THEREOF
Title (en)
NOVEL CENTROSOME-ASSOCIATED PROTEIN AND APPLICATIONS THEREOF
Title (de)
NEUESCENTROSOM-ASSOZIIERTES PROTEIN UND DESSEN ANWENDUNGEN
Title (fr)
NOUVELLE PROTEINE ASSOCIEE AUX CENTROSOMES ET SES APPLICATIONS
Publication
Application
Priority
- FR 0303895 W 20031224
- FR 0216648 A 20021224
Abstract (en)
[origin: FR2849039A1] Isolated protein (I) that: (a) has a 647 amino acid (aa) sequence (1), fully defined in the specification; or (b) has, overall, at least 80, preferably 90, % identity or at least 90, preferably 95, % similarity with (1) is new. Independent claims are also included for the following: (1) peptide (Ia) comprising a fragment of (I) with at least 10 aa; (2) variant (Ib) of (1) that includes a mutation that renders the protein dysfunctional; (3) isolated polynucleotide (II), and its fragments, variants or complements, that encode (I)-(Ib); (4) primers for amplification of (II), as RNA or genomic DNA; (5) polynucleotide (IIa) produced by amplification with the primers of (4); (6) method for determining the transcription profile of the gene corresponding to (II) or (IIa); (7) method for detecting other forms of the gene corrresponding to (II) or (IIa); (8) kit for performing methods (6) and (7); (9) cloning and/or expression vector containing (II), (IIa) or their fragments; (10) transformed host cells containing at least one (II), (IIa), their fragments or the vectors of (9); (11) transgenic, non-human organisms in which at least some cells contain at least one (II), (IIa), their fragments or the vectors of (9), in free or integrated forms; (12) preparation of (I)-(Ib) by growing cells of (10) or organisms of (11); (13) protein (Ic) produced by method (12); (14) mono- or poly-clonal antibodies (Ab) that recognize (I)-(Ic) specifically; (15) method for detecting (I)-(Ic) using Ab; (16) in vitro method for evaluating the proliferation capacity or aggressiveness of cancer cells; (17) kit for performing methods (15) or (16); and (18) method of screening for substances that can (a) interact in vitro, directly or indirectly, with (I)-(Ic), (II) or (IIa) or (b) modulate activity of (I)-(Ic).
IPC 1-7
C07K 14/435; C12N 15/12; C12N 15/63; C12N 5/10; C12Q 1/68; C07K 16/18; G01N 33/50; A61K 48/00; A61K 39/395; A61K 38/17; A61P 35/00
IPC 8 full level
A61P 35/00 (2006.01); C07K 14/47 (2006.01); C12N 15/12 (2006.01); C12Q 1/68 (2006.01); A61K 38/00 (2006.01)
CPC (source: EP US)
A61P 35/00 (2017.12 - EP); A61P 43/00 (2017.12 - EP); C07K 14/47 (2013.01 - EP US); C12Q 1/6883 (2013.01 - EP US); A01K 2217/05 (2013.01 - EP US); A61K 38/00 (2013.01 - EP US); C12Q 2600/158 (2013.01 - EP US)
Citation (search report)
See references of WO 2004058815A2
Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR
DOCDB simple family (publication)
FR 2849039 A1 20040625; FR 2849039 B1 20101001; AU 2003303464 A1 20040722; AU 2003303464 A8 20040722; CA 2511436 A1 20040715; EP 1578792 A2 20050928; JP 2006526387 A 20061124; JP 4660200 B2 20110330; US 2006216710 A1 20060928; US 2009275024 A1 20091105; US 7402394 B2 20080722; WO 2004058815 A2 20040715; WO 2004058815 A3 20050317; WO 2004058815 B1 20050506
DOCDB simple family (application)
FR 0216648 A 20021224; AU 2003303464 A 20031224; CA 2511436 A 20031224; EP 03813937 A 20031224; FR 0303895 W 20031224; JP 2004563311 A 20031224; US 21651008 A 20080707; US 54049305 A 20050624